Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: Regional analyses according to the endemic context


Autoria(s): Sartori, Ana Marli C.; de Soarez, Patricia Coelho; Dutilh Novaes, Hillegonda Maria; Amaku, Marcos; de Azevedo, Raymundo Soares; Moreira, Regina Celia; Moreira Beltrao Pereira, Leila Maria; de Alencar Ximenes, Ricardo Arraes; Turchi Martelli, Celina Maria
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

23/10/2013

23/10/2013

2012

Resumo

Objective: To To conduct a cost-effectiveness analysis of a universal childhood hepatitis A vaccination program in Brazil. Methods: An age and time-dependent dynamic model was developed to estimate the incidence of hepatitis A for 24 years. The analysis was run separately according to the pattern of regional endemicity, one for South + Southeast (low endemicity) and one for the North + Northeast + Midwest (intermediate endemicity). The decision analysis model compared universal childhood vaccination with current program of vaccinating high risk individuals. Epidemiologic and cost estimates were based on data from a nationwide seroprevalence survey of viral hepatitis, primary data collection, National Health Information Systems and literature. The analysis was conducted from both the health system and societal perspectives. Costs are expressed in 2008 Brazilian currency (Real). Results: A universal immunization program would have a significant impact on disease epidemiology in all regions, resulting in 64% reduction in the number of cases of icteric hepatitis, 59% reduction in deaths for the disease and a 62% decrease of life years lost, in a national perspective. With a vaccine price of R$16.89 (US$7.23) per dose, vaccination against hepatitis A was a cost-saving strategy in the low and intermediate endemicity regions and in Brazil as a whole from both health system and society perspective. Results were most sensitive to the frequency of icteric hepatitis, ambulatory care and vaccine costs. Conclusions: Universal childhood vaccination program against hepatitis A could be a cost-saving strategy in all regions of Brazil. These results are useful for the Brazilian government for vaccine related decisions and for monitoring population impact if the vaccine is included in the National Immunization Program. (C) 2012 Elsevier Ltd. All rights reserved.

Ministry of Health of Brazil

Ministry of Health of Brazil

National Council of Technological and Scientific Development (CNPq)

National Council of Technological and Scientific Development (CNPq)

National Institute of Science and Technology for Health Technology Assessment (IATS)

National Institute of Science and Technology for Health Technology Assessment (IATS)

CNPq [306489/2010-4, 308311/2009-4]

CNPq

Identificador

VACCINE, OXFORD, v. 30, n. 52, supl. 2, Part 3, pp. 7489-7497, DEC 14, 2012

0264-410X

http://www.producao.usp.br/handle/BDPI/35555

10.1016/j.vaccine.2012.10.056

http://dx.doi.org/10.1016/j.vaccine.2012.10.056

Idioma(s)

eng

Publicador

ELSEVIER SCI LTD

OXFORD

Relação

VACCINE

Direitos

closedAccess

Copyright ELSEVIER SCI LTD

Palavras-Chave #COST-BENEFIT ANALYSIS #COST EFFECTIVENESS #HEPATITIS A #HEPATITIS A VACCINES #UNITED-STATES #ROTAVIRUS VACCINATION #IMMUNIZATION PROGRAM #CONJUGATE VACCINE #ECONOMIC-ANALYSIS #CHILDREN #ARGENTINA #INFECTION #ADOLESCENTS #PATTERNS #IMMUNOLOGY #MEDICINE, RESEARCH & EXPERIMENTAL
Tipo

article

original article

publishedVersion